中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2014年
12期
1471-1472,1474
,共3页
疏风解毒胶囊%老年患者%社区获得性肺炎%疗效评价
疏風解毒膠囊%老年患者%社區穫得性肺炎%療效評價
소풍해독효낭%노년환자%사구획득성폐염%료효평개
Shufeng jiedu capsule%Elderly patient%Community acquired pneumonia%Curative effect
目的：评价疏风解毒胶囊治疗老年社区获得性肺炎(community acquired pneumonia，CAP)的临床疗效及安全性。方法：将100例老年CAP病人入院随机分成治疗组与对照组。治疗组病人予莫西沙星静滴，0.4g/d，连续7日，同时予疏风解毒胶囊口服，每次4粒，每日3次，连续7日；对照组予莫西沙星静脉滴注，0.4g/d，连续7日。观察两组病人治疗前后主要临床症状、体征、感染性相关指标、胸片DR变化情况，并评定病人临床治疗效果、不良反应发生情况。结果：与对照组比较，治疗组主要临床症状、体征恢复时间明显缩短(P＜0.05)，退热疗效尤其显著（P＜0.01），而且血白细胞、中性粒细胞比例、C反应蛋白及降钙素原等感染性指标在治疗后第3日显著降低（P＜0.05，P＜0.01），第7日基本恢复正常；胸部DR提示治疗组炎症病灶完全吸收率明显高于对照组(P＜0.05)；治疗组总有效率明显高于对照组(P＜O.05)。两组均未见严重不良反应发生。结论：疏风解毒胶囊联合莫西沙星治疗能促进老年CAP病人临床症状的改善，加速病人恢复。
目的：評價疏風解毒膠囊治療老年社區穫得性肺炎(community acquired pneumonia，CAP)的臨床療效及安全性。方法：將100例老年CAP病人入院隨機分成治療組與對照組。治療組病人予莫西沙星靜滴，0.4g/d，連續7日，同時予疏風解毒膠囊口服，每次4粒，每日3次，連續7日；對照組予莫西沙星靜脈滴註，0.4g/d，連續7日。觀察兩組病人治療前後主要臨床癥狀、體徵、感染性相關指標、胸片DR變化情況，併評定病人臨床治療效果、不良反應髮生情況。結果：與對照組比較，治療組主要臨床癥狀、體徵恢複時間明顯縮短(P＜0.05)，退熱療效尤其顯著（P＜0.01），而且血白細胞、中性粒細胞比例、C反應蛋白及降鈣素原等感染性指標在治療後第3日顯著降低（P＜0.05，P＜0.01），第7日基本恢複正常；胸部DR提示治療組炎癥病竈完全吸收率明顯高于對照組(P＜0.05)；治療組總有效率明顯高于對照組(P＜O.05)。兩組均未見嚴重不良反應髮生。結論：疏風解毒膠囊聯閤莫西沙星治療能促進老年CAP病人臨床癥狀的改善，加速病人恢複。
목적：평개소풍해독효낭치료노년사구획득성폐염(community acquired pneumonia，CAP)적림상료효급안전성。방법：장100례노년CAP병인입원수궤분성치료조여대조조。치료조병인여막서사성정적，0.4g/d，련속7일，동시여소풍해독효낭구복，매차4립，매일3차，련속7일；대조조여막서사성정맥적주，0.4g/d，련속7일。관찰량조병인치료전후주요림상증상、체정、감염성상관지표、흉편DR변화정황，병평정병인림상치료효과、불량반응발생정황。결과：여대조조비교，치료조주요림상증상、체정회복시간명현축단(P＜0.05)，퇴열료효우기현저（P＜0.01），이차혈백세포、중성립세포비례、C반응단백급강개소원등감염성지표재치료후제3일현저강저（P＜0.05，P＜0.01），제7일기본회복정상；흉부DR제시치료조염증병조완전흡수솔명현고우대조조(P＜0.05)；치료조총유효솔명현고우대조조(P＜O.05)。량조균미견엄중불량반응발생。결론：소풍해독효낭연합막서사성치료능촉진노년CAP병인림상증상적개선，가속병인회복。
[ABSTRACT]Objective:To evaluate shufeng jiedu capsule (SFJDC) in the treatment of the elderly patients with community-acquired pneumonia (CAP) of clinical curative effect and security.Methods:100 elderly inpatients with CAP were randomly divided into treatment group and control group.Treatment group with moxilfoxacin, 0.4 g/d, meanwhile, taking SFJDC 4 pills, 3 times a day, for 7 days;control group with moxilfoxacin, 0.4 g/d, for 7 days.Then, Observed the change of all of the patients' clinical performance, infectious related indicators and DR after treatment, and assessed the clinical curative effect and adverse reactions. Results:Major clinical symptoms and signs of recovery time of treatment group less than control group (P<0.05), especially in defervescence (P<0.01);the proportion of blood leukocytes and neutrophils, c-reactive protein and procalcitonin after 3 days for treatment group decreased signiifcantly (P<0.05, P<0.01), the 7th to generally normal;inlfammatory lesions absorption to treatment group was obviously faster than that of control group compared by DR (P<0.05);the total curative effect for treatment group was higher than that of control group (P<0.05).There were no serious adverse reactions in the two groups.Conclusion:SFJDC with moxilfoxacin can promote the improvement of the clinical symptoms of old patients with CAP, and accelerate the patient's recovery.
